基于胸腔积液中同型半胱氨酸和癌胚抗原的新型工具的恶性胸腔积液风险：一项多中心研究。

IF 2.5 3区医学 Q2 MEDICAL LABORATORY TECHNOLOGY

Clinical biochemistry Pub Date : 2024-11-13 DOI:10.1016/j.clinbiochem.2024.110841

Jose D. Santotoribio , Juan Corral-Pérez , David Nuñez-Jurado , Daniel Fatela-Cantillo , Ángela García-De La Torre , Gabriel Orantes-Maroto , Luis Del Valle-Vázquez , Daniel Del Castillo-Otero , Nieves Maira-Gonzalez , Andrés Cobos-Díaz , Juan M. Guerrero , Juan-Bosco Lopez-Saez

{"title":"基于胸腔积液中同型半胱氨酸和癌胚抗原的新型工具的恶性胸腔积液风险：一项多中心研究。","authors":"Jose D. Santotoribio , Juan Corral-Pérez , David Nuñez-Jurado , Daniel Fatela-Cantillo , Ángela García-De La Torre , Gabriel Orantes-Maroto , Luis Del Valle-Vázquez , Daniel Del Castillo-Otero , Nieves Maira-Gonzalez , Andrés Cobos-Díaz , Juan M. Guerrero , Juan-Bosco Lopez-Saez","doi":"10.1016/j.clinbiochem.2024.110841","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>This multicenter study aimed to evaluate the Malignant Pleural Effusion Risk (MPER) diagnostic accuracy in distinguishing between benign and malign pleural effusion. Methods: MPER is based on pleural fluid Homocysteine (HCY) and carcinoembryonic antigen (CEA) that were measured using three different methods. MPER was calculated by assessing a previously published probabilistic model: Probability (%) = 100× (1 + e-z)-1, where Z = 0.5471 × [HCY] + 0.3846 × [CEA]–8.2671.</div></div><div><h3>Results</h3><div>A total of 301 patients were included (140 MPE). MPER demonstrated a high AUC (0.891), sensitivity (84.3 %), and specificity (80.7 %) with a cut-off > 35.3 %.</div></div><div><h3>Conclusions</h3><div>The MPER model demonstrated a high diagnostic accuracy supporting its use as a novel and powerful tool.</div></div>","PeriodicalId":10172,"journal":{"name":"Clinical biochemistry","volume":"135 ","pages":"Article 110841"},"PeriodicalIF":2.5000,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Malignant pleural effusion risk based on a novel tool using homocysteine and carcinoembryonic antigen in pleural fluid: A multicenter study\",\"authors\":\"Jose D. Santotoribio , Juan Corral-Pérez , David Nuñez-Jurado , Daniel Fatela-Cantillo , Ángela García-De La Torre , Gabriel Orantes-Maroto , Luis Del Valle-Vázquez , Daniel Del Castillo-Otero , Nieves Maira-Gonzalez , Andrés Cobos-Díaz , Juan M. Guerrero , Juan-Bosco Lopez-Saez\",\"doi\":\"10.1016/j.clinbiochem.2024.110841\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><div>This multicenter study aimed to evaluate the Malignant Pleural Effusion Risk (MPER) diagnostic accuracy in distinguishing between benign and malign pleural effusion. Methods: MPER is based on pleural fluid Homocysteine (HCY) and carcinoembryonic antigen (CEA) that were measured using three different methods. MPER was calculated by assessing a previously published probabilistic model: Probability (%) = 100× (1 + e-z)-1, where Z = 0.5471 × [HCY] + 0.3846 × [CEA]–8.2671.</div></div><div><h3>Results</h3><div>A total of 301 patients were included (140 MPE). MPER demonstrated a high AUC (0.891), sensitivity (84.3 %), and specificity (80.7 %) with a cut-off > 35.3 %.</div></div><div><h3>Conclusions</h3><div>The MPER model demonstrated a high diagnostic accuracy supporting its use as a novel and powerful tool.</div></div>\",\"PeriodicalId\":10172,\"journal\":{\"name\":\"Clinical biochemistry\",\"volume\":\"135 \",\"pages\":\"Article 110841\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2024-11-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical biochemistry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0009912024001358\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICAL LABORATORY TECHNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical biochemistry","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0009912024001358","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

简介：这项多中心研究旨在评估恶性胸腔积液风险（MPER）诊断良性和恶性胸腔积液的准确性：这项多中心研究旨在评估恶性胸腔积液风险（MPER）在区分良性和恶性胸腔积液方面的诊断准确性：MPER基于胸腔积液中的高半胱氨酸（HCY）和癌胚抗原（CEA），采用三种不同的方法进行测量。MPER 是通过评估之前公布的概率模型计算得出的：概率 (%) = 100× (1 + e-z)-1，其中 Z = 0.5471 × [HCY] + 0.3846 × [CEA]-8.2671：共纳入 301 例患者（140 例 MPE）。MPER 的 AUC（0.891）、灵敏度（84.3%）和特异度（80.7%）都很高，临界值大于 35.3%：MPER 模型显示出很高的诊断准确性，支持将其用作一种新颖而强大的工具。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Malignant pleural effusion risk based on a novel tool using homocysteine and carcinoembryonic antigen in pleural fluid: A multicenter study

Introduction

This multicenter study aimed to evaluate the Malignant Pleural Effusion Risk (MPER) diagnostic accuracy in distinguishing between benign and malign pleural effusion. Methods: MPER is based on pleural fluid Homocysteine (HCY) and carcinoembryonic antigen (CEA) that were measured using three different methods. MPER was calculated by assessing a previously published probabilistic model: Probability (%) = 100× (1 + e-z)-1, where Z = 0.5471 × [HCY] + 0.3846 × [CEA]–8.2671.

Results

A total of 301 patients were included (140 MPE). MPER demonstrated a high AUC (0.891), sensitivity (84.3 %), and specificity (80.7 %) with a cut-off > 35.3 %.

Conclusions

The MPER model demonstrated a high diagnostic accuracy supporting its use as a novel and powerful tool.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical biochemistry 医学-医学实验技术

CiteScore

5.10

自引率

0.00%

发文量

151

审稿时长

25 days

期刊介绍： Clinical Biochemistry publishes articles relating to clinical chemistry, molecular biology and genetics, therapeutic drug monitoring and toxicology, laboratory immunology and laboratory medicine in general, with the focus on analytical and clinical investigation of laboratory tests in humans used for diagnosis, prognosis, treatment and therapy, and monitoring of disease.